凝血四项、vWF、抗Xa和肿瘤标志物检测在西黄丸治疗晚期胃癌中的应用  

An Application of Coagulation Tests,vWF,Anti-Xa,and Tumor Marker Detection in the Treatment of Advanced Gastric Cancer with Xihuang Pill

在线阅读下载全文

作  者:杨琦[1] 王斌[1] 栗晓彬 张泽[1] 李洪敏 刘扬[1] 宋天佳 林英[1] YANG Qi;WANG Bin;LI Xiaobin;ZHANG Ze;LI Hongmin;LIU Yang;SONG Tianjia;LIN Ying(Medical Clinical Lab,Dongzhimen Hospital,Beijing University of Traditional Chinese Medicine,Beijing 100700,China)

机构地区:[1]北京中医药大学东直门医院检验科,北京100700

出  处:《标记免疫分析与临床》2025年第3期474-479,共6页Labeled Immunoassays and Clinical Medicine

基  金:《国产凝血产品vWFAg和抗Xa试剂盒产学协同研发项目》(编号:22097010274456)。

摘  要:目的探讨凝血四项、vWF、抗Xa和肿瘤标志物检测在西黄丸治疗晚期胃癌中的应用价值。方法选取晚期胃癌患者120例作为研究对象,按照随机表法分组,各60例。对照组给予奥沙利铂+卡培他滨(XELOX)化疗,研究组在对照组基础上给予西黄丸。比较两组治疗效果、治疗前后vWF、抗Xa、凝血四项[活化部分凝血酶原时间(APTT)、凝血酶时间(TT)、纤维蛋白原(FIB)、D-二聚体(D-D)]、肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原19-9(CA19-9)、糖类抗原72-4(CA72-4)]及不良反应,并统计对比两组病例1年生存率、无进展生存期。结果研究组疾病控制率高于对照组(P<0.05);研究组治疗后抗Xa、APTT、TT较治疗前升高,且高于对照组,vWF、FIB、D-D较治疗前下降,且低于对照组(P<0.05),对照组治疗后vWF、抗Xa、APTT、TT、FIB、D-D与治疗前差异无统计学意义(P>0.05);治疗后血清CEA、CA125、CA19-9、CA72-4水平较治疗前下降,研究组低于对照组(P<0.05);研究组恶心呕吐、骨髓抑制发生率低于对照组(P<0.05);研究组1年生存率高于对照组,无进展生存期长于对照组(P<0.05)。结论凝血指标及肿瘤标志物的检测,可用于西黄丸治疗晚期胃癌效果的监测,西黄丸可显著提高疾病控制率,抑制肿瘤标志物表达,改善生存预后,这与其抗血液高凝状态的作用机制有关。Objective To explore the application value of coagulation tests,vWF,anti-Xa,and tumor marker detection in the treatment of advanced gastric cancer with Xihuang Pill.Methods A total of 120 patients with advanced gastric cancer were selected as the study objects,and then divided into groups with 60 cases each according to random table method.The control group was given oxaliplatin+capecitabine(XELOX)chemotherapy,while the study group was given Xihuang Pill in addition to the control group.The treatment effects of the two groups were compared.The comparisons of before and after the treatment for vWF,anti-Xa,four items of coagulation[activated partial thromboplastin time(APTT),prothrombin time(TT),fibrinogen(FIB),and D-dimer(D-D)],tumor markers[carcinoembryonic antigen(CEA),glycan antigen 125(CA125),glycan antigen 19-9(CA19-9),and glycan antigen 72-4(CA72-4)]were conducted,as well as the comparison of the adverse effects between the two groups.We also compared the 1-year survival rate and progression-free survival of the two groups.Results The disease control rate of the study group was significantly higher than that of the control group(P<0.05).After treatment,anti-Xa,APTT and TT in the study group were increased compared with before treatment,and significantly higher than that in the control group;vWF,FIB and D-D were decreased compared with before treatment,and significantly lower than that in the control group(P<0.05);vWF,anti-Xa,APTT,TT,FIB and D-D in the control group were not significantly different from after treatment(P>0.05);Serum levels of ESM-1,VEGF and NRP-1 were significantly lower in the study group than in the control group after of treatment(P<0.05).The levels of CEA,CA125,CA19-9 and CA72-4 in the study group were significantly lower than those in the control group after of treatment(P<0.05).The incidence of nausea,vomiting and myelosuppression in the study group was significantly lower than that in the control group(P<0.05).The 1-year survival rate of the study group was significantly higher than th

关 键 词:西黄丸 晚期胃癌 血管性血友病因子 凝血因子抗Xa 凝血四项 治疗作用 

分 类 号:R446[医药卫生—诊断学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象